Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Chroma Therapeutics
Woman and Man Max 99 years
Chroma Therapeutics Ltd
Update Il y a 4 ans
A Phase I-II Study to Evaluate the Safety, Tolerability and Anti-Disease Activity of the Aminopeptidase Inhibitor, CHR-2797, in Elderly and/or Treatment Refractory Patients with Acute Myeloid Leukaemia or Multiple Myeloma
Primary objective(s): • (Phase I) To determine the safety, tolerability, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of CHR-2797 when administered orally, once daily, to elderly pati...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Chroma Therapeutics Ltd
Update Il y a 4 ans
The OPAL Study: A Phase II Single Arm Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia
The primary objective of the study is to evaluate the efficacy of tosedostat in elderly subjects with treatment refractory or relapsed AML by measuring CR and CRp.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Chroma Therapeutics
Update Il y a 4 ans
CHROMA THERAPEUTICS CHR-2845-001 : Essai de phase 1 évaluant la tolérance d’un inhibiteur d’histone déacétylase (CHR-2845), chez des patients ayant une hémopathie maligne avancée ou réfractaire aux traitements. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase I study to evaluate the safety and tolerability of the histone deacetylase inhibitor, CHR-2845, in patients with advanced or treatment refractory haematological diseases or lymphoid malignanci...
Country
France
organs
Tout cancer hématologique
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information